{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T02:17:00Z","timestamp":1780712220240,"version":"3.54.1"},"reference-count":38,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"47","license":[{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,11]]},"abstract":"<jats:sec>\n            <jats:title>Abstract<\/jats:title>\n            <jats:p>The study evaluates efficacy and safety of recombinant human parathyroid hormone (1\u201334) [rhPTH (1\u201334)] and alendronate (ALN) in the treatment of postmenopausal osteoporosis.<\/jats:p>\n            <jats:p>Totally 65 postmenopausal women with osteoporosis were divided into 2 groups. PTH group received daily subcutaneous injection of rhPTH (1\u201334), and ALN group were treated orally with ALN per week. Bone mineral density (BMD) of lumbar spine (1\u20134), femoral neck, and total hip, serum levels of calcium, phosphorus, total cholesterol, triglyceride, alkaline phosphatase (ALP), N-terminal propeptide of type I collagen (PINP), and C-telopeptide of type I collagen (CTX) were tested before treatment and at week 24 and 48 after treatment. Serum levels of vascular endothelial growth factor (VEGF) and platelet-derived growth factor-BB (PDGF-BB) were measured before treatment and at week 48 after treatment.<\/jats:p>\n            <jats:p>The rhPTH (1\u201334) increased BMD of lumbar spine (1\u20134), but decreased BMD of femoral neck and total hip at week 48 after treatment. By contrast, ALN enhanced BMD of lumbar spine (1\u20134) and femoral neck, but reduced BMD of total hip at week 48 after treatment. In PTH group, serum levels of PINP, ALP, and \u03b2-CTX were significantly elevated above baseline at week 24 and 48 after treatment. Treatment with ALN decreased levels of PINP, ALP, and \u03b2-CTX compared with baseline at week 24 and 48 after treatment. rhPTH (1\u201334) and ALN significantly decreased levels of PDGF-BB, but not levels of VEGF. rhPTH (1\u201334) increased levels of calcium, phosphorus and triglyceride, but decreased levels of total cholesterol. ALN increased levels of calcium and triglyceride, but reduced levels of phosphorus and total cholesterol. rhPTH (1\u201334) and ALN were safe in the treatment of postmenopausal osteoporosis.<\/jats:p>\n            <jats:p>The study demonstrates that efficacy of rhPTH (1\u201334) on BMD of lumbar spine (1\u20134) is similar to that of alendronate in the treatment of postmenopausal osteoporosis. The effect of rhPTH (1\u201334) on BMD of femoral neck or total hip is weaker than that of ALN. In addition, rhPTH (1\u201334) increases BMD of lumbar spine (1\u20134) maybe by raising serum levels of VEGF, but reduces BMD of femoral neck and total hip maybe by decreasing serum levels of PDGF-BB.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000013341","type":"journal-article","created":{"date-parts":[[2018,11,21]],"date-time":"2018-11-21T04:27:05Z","timestamp":1542774425000},"page":"e13341","source":"Crossref","is-referenced-by-count":11,"title":["Efficacy and safety of recombinant human parathyroid hormone (1\u201334) are similar to those of alendronate in the treatment of postmenopausal osteoporosis"],"prefix":"10.1097","volume":"97","author":[{"given":"Jing","family":"Deng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhengping","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tingting","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qifu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changhong","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20230914","first-page":"228","article-title":"Osteoporosis [in German]","volume":"39","author":"Hintze","year":"2016","journal-title":"Med Monatsschr Pharm"},{"key":"R2-20230914","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1055\/s-0034-1384629","article-title":"Insights into the epidemiology of postmenopausal osteoporosis: the women's health initiative","volume":"32","author":"Jackson","year":"2014","journal-title":"Semin Reprod Med"},{"key":"R3-20230914","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1152\/ajplegacy.1973.225.2.269","article-title":"Decreased bone formation, mineralization, and enhanced resorption in calcium-deficient rats","volume":"225","author":"Stauffer","year":"1973","journal-title":"Am J Physiol"},{"key":"R4-20230914","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1007\/BF02405394","article-title":"Mechanisms of bone resorption in calcium-deficiet rats","volume":"36","author":"Sissons","year":"1984","journal-title":"Calcif Tissue Int"},{"key":"R5-20230914","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.bone.2010.11.008","article-title":"Biochemical and molecular mechanisms of action of bisphosphonates","volume":"49","author":"Rogers","year":"2011","journal-title":"Bone"},{"key":"R6-20230914","doi-asserted-by":"crossref","first-page":"e130","DOI":"10.1097\/MJT.0000000000000446","article-title":"Alendronate for the treatment of osteoporosis in men: a meta-analysis of randomized controlled trials","volume":"24","author":"Xu","year":"2017","journal-title":"Am J Ther"},{"key":"R7-20230914","first-page":"155","article-title":"Live imaging of osteoclast inhibition by bisphosphonates in a medaka osteoporosis model","volume":"9","author":"Yu","year":"2016","journal-title":"Dis Model Mech"},{"key":"R8-20230914","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1056\/NEJMra067395","article-title":"Mechanisms of anabolic therapies for osteoporosis","volume":"357","author":"Canalis","year":"2007","journal-title":"N Engl J Med"},{"key":"R9-20230914","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1007\/s11914-013-0171-2","article-title":"Parathyroid hormone and parathyroid hormone-related protein analogs as therapies for osteoporosis","volume":"11","author":"Augustine","year":"2013","journal-title":"Curr Osteoporos Rep"},{"key":"R10-20230914","doi-asserted-by":"crossref","first-page":"e3626","DOI":"10.1097\/MD.0000000000003626","article-title":"Teriparatide improves fracture healing and early functional recovery in treatment of osteoporotic intertrochanteric fractures","volume":"95","author":"Huang","year":"2016","journal-title":"Medicine"},{"key":"R11-20230914","doi-asserted-by":"crossref","first-page":"2624","DOI":"10.12659\/MSM.892581","article-title":"Single and combined use of human parathyroid hormone (PTH) (1\u201334) on areal bone mineral density (aBMD) in postmenopausal women with osteoporosis: evidence based on 9 RCTs","volume":"20","author":"Song","year":"2014","journal-title":"Med Sci Monit"},{"key":"R12-20230914","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/S1995-7645(14)60192-9","article-title":"Comparison between recombinant human parathyroid hormone (1\u201334) and elcatonin in treatment of primary osteoporosis","volume":"8","author":"Yang","year":"2015","journal-title":"Asian Pac J Trop Med"},{"key":"R13-20230914","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.afos.2015.07.004","article-title":"Comparative effect of alendronate and teriparatide on bone mineral density and bone turnover among Japanese postmenopausal women with history of fragility fractures: A clinical practice-based observational study","volume":"1","author":"Iwamotoa","year":"2015","journal-title":"Osteoporos Sarcopenia"},{"key":"R14-20230914","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1007\/s00223-015-0026-1","article-title":"Early effects of single and low-frequency repeated administration of teriparatide, hpth (1\u201334), on bone formation and resorption in ovariectomized rats","volume":"97","author":"Isogai","year":"2015","journal-title":"Calcif Tissue Int"},{"key":"R15-20230914","doi-asserted-by":"crossref","first-page":"6","DOI":"10.3389\/fendo.2015.00006","article-title":"Improvement of skeletal fragility by teriparatide in adult osteoporosis patients: a novel mechanostat-based hypothesis for bone quality","volume":"6","author":"Sugiyama","year":"2015","journal-title":"Front Endocrinol (Lausanne)"},{"key":"R16-20230914","doi-asserted-by":"crossref","first-page":"2409","DOI":"10.1517\/14656566.2015.1087506","article-title":"The use of bisphosphonates in women: when to use and when to stop","volume":"16","author":"Gatti","year":"2015","journal-title":"Expert Opin Pharmacother"},{"key":"R17-20230914","first-page":"105","article-title":"Treatment of primary osteoporosis in men","volume":"10","author":"Giusti A","year":"2014","journal-title":"Clin Interv Aging"},{"key":"R18-20230914","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1007\/s12020-014-0506-5","article-title":"Bisphosphonates in the treatment of glucocorticoid-induced osteoporosis: pros","volume":"49","author":"Rossini","year":"2015","journal-title":"Endocrine"},{"key":"R19-20230914","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1001\/archinte.165.15.1762","article-title":"Opposite bone remodeling effects of teriparatide and alendronate in increasing bone mass","volume":"165","author":"McClung","year":"2005","journal-title":"Arch Intern Med"},{"key":"R20-20230914","doi-asserted-by":"crossref","first-page":"e26267","DOI":"10.1371\/journal.pone.0026267","article-title":"Parathyroid hormone versus bisphosphonate treatment on bone mineral density in osteoporosis therapy: a meta-analysis of randomized controlled trials","volume":"6","author":"Shen","year":"2011","journal-title":"PLoS One"},{"key":"R21-20230914","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.bone.2010.05.022","article-title":"Effects of teriparatide on bone mineral density and bone turnover markers in Japanese subjects with osteoporosis at high risk of fracture in a 24-month clinical study: 12-month, randomized, placebo-controlled, double-blind and 12-month open-label phases","volume":"47","author":"Miyauchi","year":"2010","journal-title":"Bone"},{"key":"R22-20230914","doi-asserted-by":"crossref","first-page":"4528","DOI":"10.1210\/jc.2002-020334","article-title":"A randomized double-blind trial to compare the efficacy of teriparatide [recombinant human parathyroid hormone (1\u201334)] with alendronate in postmenopausal women with osteoporosis","volume":"87","author":"Body","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"R23-20230914","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S8756-3282(00)00422-1","article-title":"Tie2 ligands angiopoietin-1 and angiopoietin-2 are coexpressed with vascular endothelial cell growth factor in growing human bone","volume":"28","author":"Horner","year":"2001","journal-title":"Bone"},{"key":"R24-20230914","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.ajodo.2015.09.021","article-title":"Effects of vascular endothelial growth factor on osteoblasts and osteoclasts","volume":"149","author":"Huang","year":"2016","journal-title":"Am J Orthod Dentofacial Orthop"},{"key":"R25-20230914","first-page":"446","article-title":"Study on RhBMP-2 induced osteoporosis rat BMSCs in vitro osteogenesis and VEGF expression [in Chinese]","volume":"28","author":"Li","year":"2015","journal-title":"Zhongguo Gu Shang"},{"key":"R26-20230914","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.bone.2016.06.013","article-title":"The roles of vascular endothelial growth factor in bone repair and regeneration","volume":"91","author":"Hu","year":"2016","journal-title":"Bone"},{"key":"R27-20230914","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.ydbio.2015.07.014","article-title":"Vascular endothelial growth factor signaling affects both angiogenesis and osteogenesis during the development of scleral ossicles","volume":"406","author":"Jabalee","year":"2015","journal-title":"Dev Biol"},{"key":"R28-20230914","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1172\/JCI82585","article-title":"Osteoblast-derived VEGF regulates osteoblast differentiation and bone formation during bone repair","volume":"126","author":"Hu","year":"2016","journal-title":"J Clin Invest"},{"key":"R29-20230914","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.cyto.2009.03.012","article-title":"Factors regulating circulating vascular endothelial growth factor (VEGF): association with bone mineral density (BMD) in post-menopausal osteoporosis","volume":"46","author":"Costa","year":"2009","journal-title":"Cytokine"},{"key":"R30-20230914","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1681\/ASN.V1161085","article-title":"C-terminal parathyroid hormone-related protein increases vascular endothelial growth factor in human osteoblastic cells","volume":"11","author":"Esbrit","year":"2000","journal-title":"J Am Soc Nephrol JASN"},{"key":"R31-20230914","doi-asserted-by":"crossref","first-page":"349-","DOI":"10.1016\/j.bone.2011.05.003","article-title":"Effects of intermittent parathyroid hormone treatment on osteoprogenitor cells in postmenopausal women","volume":"49","author":"Drake","year":"2011","journal-title":"Bone"},{"key":"R32-20230914","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1002\/jcp.21547","article-title":"Parathyroid hormone-related protein (107-139) increases human osteoblastic cell survival by activation of vascular endothelial growth factor receptor-2","volume":"217","author":"Alonso","year":"2008","journal-title":"J Cell Physiol"},{"key":"R33-20230914","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1038\/nm.3668","article-title":"PDGF-BB secreted by preosteoclasts induces angiogenesis during coupling with osteogenesis","volume":"20","author":"Xie","year":"2014","journal-title":"Nat Med"},{"key":"R34-20230914","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.bbrc.2015.04.115","article-title":"Secretion of PDGF isoforms during osteoclastogenesis and its modulation by anti-osteoclast drugs","volume":"462","author":"Rahman","year":"2015","journal-title":"BiochBioem Biophys Res Commun"},{"key":"R35-20230914","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1185\/03007995.2012.659724","article-title":"Mixed-treatment comparison of anabolic (teriparatide and PTH 1-84) therapies in women with severe osteoporosis","volume":"28","author":"Migliore","year":"2012","journal-title":"Curr Med Res Opin"},{"key":"R36-20230914","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.drudis.2013.07.015","article-title":"Treating osteoporosis by targeting parathyroid hormone to bone","volume":"19","author":"Ponnapakkam","year":"2014","journal-title":"Drug Discov Today"},{"key":"R37-20230914","first-page":"931","article-title":"Treatment with teriparatide might be associated with cardiometabolic changes in postmenopausal severe osteoporotic women","volume":"29","author":"Passeri","year":"2015","journal-title":"J Biol Regul Homeost Agents"},{"key":"R38-20230914","doi-asserted-by":"crossref","first-page":"E1982","DOI":"10.1210\/jc.2011-0587","article-title":"Change in undercarboxylated osteocalcin is associated with changes in body weight, fat mass, and adiponectin: parathyroid hormone (1\u201384) or alendronate therapy in postmenopausal women with osteoporosis (the PaTH study)","volume":"96","author":"Schafer","year":"2011","journal-title":"J Clin Endocrinol Metab"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00005792-201811210-00055","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,14]],"date-time":"2023-09-14T17:14:29Z","timestamp":1694711669000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00005792-201811210-00055"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11]]},"references-count":38,"journal-issue":{"issue":"47","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000013341","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,11]]}}}